PreludeDx

The summer months can pose additional challenges for women receiving #breastcancer treatment. Increased sun sensitivity, dehydration risk and fatigue are just a few of the concerns. This article explores strategies for managing these issues and enjoying the summer season safely and comfortably: https://lnkd.in/gjz8K7Ny

Congratulations to our team and our great collaborators on making a difference for breast cancer patients.

The PREDICT study, a landmark trial enrolling 2,000+ women with #DCIS across 63 U.S. academic and community centers, is now published in the Annals of Surgical Oncology. This research reinforces the clinical utility of our #DCISionRT test in personalizing treatment, demonstrating a 38% change in radiation therapy (RT) recommendations. This prospective study highlights the test’s ability to help avoid both over- and undertreatment of DCIS. Learn how #DCISionRT empowers informed decisions and improves patient care. https://lnkd.in/gH7Fk78p

Dr. Tracy E. Alpert, a radiation oncologist at Hematology-Oncology Associates of CNY, shares how the #DCISionRT test transforms her approach #breastcancer treatment.  By providing quantitative data on the potential benefits of radiation therapy for #DCIS patients, the test empowers both physicians and patients to make more informed decisions. In this interview, she emphasizes the importance of embracing genomic tests in oncology to make sure patients receive the most appropriate and effective treatment. https://lnkd.in/g5hv_6vq

Pat Whitworth CMO of PreludeDx, delivers important new data at #ASCO24 about the ability of DCISionRT to predict benefit of radiation therapy in DCIS patients, independent of endocrine therapy.

We’re proud to participate at American Society of Clinical Oncology (ASCO) where we’ll present new data during our poster presentation about the clinical utility of our #DCISionRT test to personalize radiation treatment for women with #DCIS, independent of endocrine therapy use. #ASCO24 https://lnkd.in/gagRe7RS

We’re proud to participate at American Society of Clinical Oncology (ASCO) where we’ll present new data during our poster presentation about the clinical utility of our #DCISionRT test to personalize radiation treatment for women with #DCIS, independent of endocrine therapy use. #ASCO24 https://lnkd.in/gagRe7RS

In a recent @Onco’Zine article, @AmishiBajajMD, Radiation Oncology, @NorthwesternMed and @ChicagoProton, addresses the question ‘to what extent does the #DCISionRT biosignature predict for local recurrence events as compared to only clinicopathologic (CP) factors for patients diagnosed with ductal carcinoma in situ (#DCIS). Dr. Bajaj reviews data presented at the @ASTRO23 meeting comparing the DCISionRT biosignature to criteria from RTOG 9804 along with criteria supported by the Memorial Sloan Kettering Cancer Center (MSKCC) DCIS nomogram. Dr. Bajaj concluded the DCISionRT 7-gene biosignature more reliably predicted higher rates of recurrence for patients who were deemed low risk by CP alone but high risk by biosignature. Accordingly, the DCISionRT 7-gene biosignature also predicted for low-risk patients who would not benefit from adjuvant RT. These new data demonstrate that the DCISionRT biosignature reclassified nearly half of the CP low-risk patients as biosignature high risk with an increased 10-year IBR rate and significant RT benefits. https://bit.ly/49GuaiR #bcsm #breastcancer #PreludeDx

Women’s Health Month reminds us that collaboration is key. Researchers, clinicians, advocates and patients-we all have a role in advancing women’s health. Let’s continue to work together to drive breakthroughs and ensure better health outcomes for women everywhere. #WomensHealthMonth

“Dr. Whitworth’s deep knowledge of breast cancer surgery, his passion for research and his dedication to patient advocacy and innovation, make him an ideal fit for PreludeDx,” said Dan Forche, President and CEO of PreludeDx. https://lnkd.in/gQQcmE28